TY - JOUR
T1 - Clinical and endoscopic findings to assist the early detection of duodenal adenoma and adenocarcinoma
AU - Matsuzaki, Juntaro
AU - Suzuki, Hidekazu
AU - Shimoda, Masayuki
AU - Mori, Hideki
AU - Fukuhara, Seiichiro
AU - Miyoshi, Sawako
AU - Masaoka, Tatsuhiro
AU - Iwao, Yasushi
AU - Kanai, Yae
AU - Kanai, Takanori
N1 - Funding Information:
This work was supported by a Grant-in-Aid for Young Scientists B (26860527 to JM), a Grant-in-Aid for Scientific Research B (16H05291, to HS), a Grant-in-Aid for Scientific Research C (17K09471 to JM), and a Grant-in-Aid for Challenging Exploratory Research (26670065 to HS) from the Japan Society for the Promotion of Science, MEXT-Supported Program for the Strategic Research Foundation at Private Universities (S1411003 to HS), the Princess Takamatsu Cancer Research grants (to HS), a grant from Takeda Science Foundation (to JM), and Keio Gijuku Academic Development Funds (to JM and to HS). The sponsors had no roles in study design, data collection, data analysis, data interpretation, or writing of the report.
Funding Information:
During the last two years, HS received scholarship funds from Daiichi-Sankyo, Co., Otsuka Pharmaceutical Co Ltd, Tsumura Co Ltd, and Tsumura Co to conduct the research. HS received service honoraria from Astellas Pharma Inc, AstraZeneca K.K., Daiichi-Sankyo, Co., Otsuka Pharmaceutical Co Ltd, Takeda Pharmaceutical Co Ltd, Tsumura Co., Mylan EPD Co, and Zeria Pharmaceutical Co Ltd. TK received scholarship funds from Astellas Pharma Inc, AstraZeneca K.K., Otsuka Pharmaceutical Co Ltd, Takeda Pharmaceutical Co Ltd, Eisai Pharmaceutical Co Ltd, Zeria Pharmaceutical Co Ltd, Tanabe Mitsubishi Pharmaceutical Co Ltd, JIMRO Co Ltd, and Kyorin Pharmaceutical Co Ltd to conduct the research. TK received service honoraria from Astellas Pharma Inc, Eisai Pharmaceutical Co Ltd, JIMRO Co Ltd, Tanabe Mitsubishi Pharmaceutical Co Ltd, Otsuka Pharmaceutical Co Ltd, Takeda Pharmaceutical Co Ltd, Miyarisan Pharmaceutical Co Ltd, and Zeria Pharmaceutical Co Ltd. The other authors have nothing to declare.
Publisher Copyright:
© Author(s) 2018.
PY - 2019/3/1
Y1 - 2019/3/1
N2 - Background: Sporadic nonampullary duodenal adenocarcinoma is a rare malignant neoplasm in which poor prognosis is often associated with delayed diagnosis. Objective: A case-control study was designed to evaluate the clinical and endoscopic characteristics of patients with nonampullary duodenal epithelial tumours (NADETs). Methods: Patients with NADETs were chronologically divided into a discovery and a validation sets. Two age- and sex-matched control individuals for each case in the discovery set were randomly selected from individuals without NADET. A prediction model for the presence of NADET, constructed in the discovery set, was evaluated in the validation set. Results: In total, 368 adenomas, 81 adenocarcinomas, and 314 controls were analysed. Current smoking, Barrett oesophagus, fundic gland polyps, history of malignant disease, and absence of dyslipidaemia were independently associated with the presence of NADET. The combination of these five factors enabled significant discrimination for NADET in the bulb with a sensitivity of 0.81 in the validation set. We also showed that duodenal adenocarcinomas in the bulb had greater invasive potential than adenocarcinomas in the second portion. Conclusion: The presence of a duodenal tumour in the bulb could be predicted by clinical and endoscopic findings, which helps improve the prognosis and quality of life of patients.
AB - Background: Sporadic nonampullary duodenal adenocarcinoma is a rare malignant neoplasm in which poor prognosis is often associated with delayed diagnosis. Objective: A case-control study was designed to evaluate the clinical and endoscopic characteristics of patients with nonampullary duodenal epithelial tumours (NADETs). Methods: Patients with NADETs were chronologically divided into a discovery and a validation sets. Two age- and sex-matched control individuals for each case in the discovery set were randomly selected from individuals without NADET. A prediction model for the presence of NADET, constructed in the discovery set, was evaluated in the validation set. Results: In total, 368 adenomas, 81 adenocarcinomas, and 314 controls were analysed. Current smoking, Barrett oesophagus, fundic gland polyps, history of malignant disease, and absence of dyslipidaemia were independently associated with the presence of NADET. The combination of these five factors enabled significant discrimination for NADET in the bulb with a sensitivity of 0.81 in the validation set. We also showed that duodenal adenocarcinomas in the bulb had greater invasive potential than adenocarcinomas in the second portion. Conclusion: The presence of a duodenal tumour in the bulb could be predicted by clinical and endoscopic findings, which helps improve the prognosis and quality of life of patients.
KW - Atherosclerosis
KW - chronic mesenteric ischemia
KW - computed tomography angiography
KW - endovascular therapy
KW - median arcuate ligament syndrome
UR - http://www.scopus.com/inward/record.url?scp=85059338701&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85059338701&partnerID=8YFLogxK
U2 - 10.1177/2050640618817689
DO - 10.1177/2050640618817689
M3 - Article
C2 - 31080610
AN - SCOPUS:85059338701
SN - 2050-6406
VL - 7
SP - 250
EP - 260
JO - United European Gastroenterology Journal
JF - United European Gastroenterology Journal
IS - 2
ER -